Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Background: Identification of new biomarkers with potential predictive and prognostic role has contributed unequivocally to breast cancer treatment.

Although traditionally endocrine therapy is based on hormonal receptors status (estrogen - ER and progesterone- PR), some patients become hormone resistant. In order to identify a possible profile associated to hormonal resistance, some biomarkers have been assessed after short period primary hormone therapy (HT).

Objectives: To compare the expression of Ki-67, Bcl2, Bax, Bak, ER and e PR in postmenopausal women with ER positive invasive ductal carcinomas (IDC), prior and after tamoxifen and anastrozole in short term hormone therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federal University of São Paulo
• Treatments: Anastrozole; Hormones; Progesterone; Tamoxifen

Criteria

Inclusion Criteria:

• Invasive breast cancer post-menopausal women

• Estrogen and/or progesterone receptor positive

Exclusion Criteria:

• Patients with endocrine disease

• Hormone therapy users or those who had been pregnant in the last 12 months before the diagnosis

• Patients with a negative expression for estrogen and/or progesterone receptors

• Women with a history of thromboembolism

• Patients who had previously undergone any treatment for breast cancer